# Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.

> **NCT01456715** · PHASE3 · COMPLETED · sponsor: **Laval University** · enrollment: 418 (actual)

## Conditions studied

- Human Papillomavirus

## Interventions

- **BIOLOGICAL:** Gardasil vaccine, Immunogenicity, Booster dose.
- **BIOLOGICAL:** Cervarix Vaccine, Immunogenicity, Booster Dose.

## Key facts

- **NCT ID:** NCT01456715
- **Lead sponsor:** Laval University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2020-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456715, "Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01456715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*